Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 0.80% | 69.52 | 0.0% | $2214.61m | |
| NVAX | Novavax, Inc. | -16.77% | 124.42 | 96.5% | $1026.77m | |
| SRNE | Sorrento Therapeutics, Inc. | -11.92% | 12.41 | 1.5% | $731.21m | |
| GILD | Gilead Sciences, Inc. | 1.09% | 68.84 | 1.0% | $571.41m | |
| AMGN | Amgen, Inc. | 3.01% | 241.72 | 1.3% | $485.13m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.25% | 612.35 | 2.7% | $399.20m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 3.43% | 270.85 | 1.9% | $367.43m | |
| BIIB | Biogen, Inc. | 1.13% | 293.22 | 1.6% | $355.55m | |
| BNTX | BioNTech SE | 0.96% | 69.11 | 0.0% | $350.86m | |
| ILMN | Illumina, Inc. | 0.86% | 344.14 | 3.5% | $338.32m | |
| VXRT | Vaxart, Inc. | -14.42% | 9.20 | 0.0% | $262.52m | |
| ATNM | Actinium Pharmaceuticals, Inc. | -0.31% | 9.63 | 13.3% | $232.11m | |
| EBS | Emergent BioSolutions, Inc. | 6.00% | 129.67 | 6.4% | $188.23m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.52% | 102.78 | 2.0% | $167.84m | |
| SGEN | Seattle Genetics, Inc. | 3.46% | 158.79 | 6.0% | $158.72m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.